PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections
Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024
New Preclinical Data Showed OncoPLEX Injected Intratumorally Reduced Tumor Volume and Improved Survival in New Animal Models
Recent Successful
Conference Call Scheduled for Today at 8:30 AM ET
PETACH TIKVA, Israel,
Recent Corporate Highlights:
- More than 100 patients have been enrolled to date in the ongoing SHIELD II Phase 3 trial that is recruiting patients undergoing colorectal abdominal surgery with large incisions.
- Approximately 40 centers are currently open.
- Unblinded interim analysis is planned to be conducted once a total of approximately 400 patients complete their 30-day follow-up, which is expected to occur in mid-2024.
- Top-line results are anticipated in the second half of 2024.
- Approximately 40 centers are currently open.
- Generated new preclinical data with OncoPLEX injected intratumorally
- OncoPLEX single intratumoral injection significantly reduced tumor growth and increased survival in two well established and commonly used tumor animal models: murine melanoma and murine colon carcinoma.
- The intratumoral injection of the PLEX platform could be used as an interventional oncology treatment with additional chemotherapies or other types of molecules, such as monoclonal antibodies, bispecific antibodies and nucleic acids.
- OncoPLEX single intratumoral injection significantly reduced tumor growth and increased survival in two well established and commonly used tumor animal models: murine melanoma and murine colon carcinoma.
- Closed a private placement financing (the “PIPE”) for
$16 million of gross proceeds, which extends the Company’s cash runway through late in the third quarter of 2024 and beyond the expected timing of the planned unblinded interim analysis.
- PIPE syndicate was comprised of new and existing investors, including participation from new
U.S. life sciences-focused investors,DAFNA Capital Management andRosalind Advisors . - Company has the potential to secure an additional
$19 million if the results of the unblinded interim analysis are positive and all warrants issued in the recent financing are exercised, which would fundPolyPid to the start of a planned New Drug Application (“NDA”) submission for D-PLEX100.
- PIPE syndicate was comprised of new and existing investors, including participation from new
“We are thrilled with the significant progress recently achieved throughout our business,” stated Dikla Czaczkes Akselbrad, PolyPid’s Chief Executive Officer. “As we expected, enrollment in our ongoing SHIELD II Phase 3 pivotal trial for D-PLEX100 has begun to ramp up, and we continue to anticipate top-line results from this study in the second half of 2024. We have also generated new highly compelling preclinical data with OncoPLEX that demonstrate its potential in oncology and beyond.”
“Moreover, in order to support our robust clinical development efforts, we successfully completed a
Financial results for three months ended
- Research and development (R&D) expenses, net for the three months ended
December 31, 2023 , were$4.6 million , compared to$4.7 million in the same three-month period of 2022. R&D expenses in the most recently completed quarter were driven by the ramp up of the ongoing SHIELD II Phase 3 trial. - General and administrative (G&A) expenses for the three months ended
December 31, 2023 , were$1.2 million , compared to$1.6 million for the same period of 2022. - Marketing and business development expenses for the three months ended
December 31, 2023 , were$0.2 million , compared to$0.4 million for the same period of 2022. - For the three months ended
December 31, 2023 , the Company had a net loss of $6.4 million, or ($3.97 ) per diluted share, compared to a net loss of$6.6 million , or ($9.90 ) per diluted share, in the three-month period endedDecember 31, 2022 .
Financial results for the full year ended
- R&D expenses, net for the year ended
December 31, 2023 , were$16.1 million , compared to$28 million in 2022. The decrease in R&D expenses resulted primarily from the completion of the SHIELD I Phase 3 clinical trial. - G&A expenses for the year ended
December 31, 2023 , were$5.5 million , compared to$8.0 million for 2022. - Marketing and business development expenses for the year ended
December 31, 2023 , were$1.2 million , compared to$2.9 million for 2022. - The decreases in G&A and marketing and business development expenses were primarily due to the Company’s cost reduction plan announced in October 2022 and further cost savings initiatives implemented during full year 2023.
- For the year ended
December 31, 2023 , the Company had a net loss of $23.9 million, or ($16.93 ) per diluted share, compared to a net loss of$39.6 million , or ($61.09 ) per diluted share, for 2022.
Balance Sheet Highlights
- As of December 31, 2023, the Company had cash and cash equivalents in the amount of
$5.3 million . This does not include the net proceeds of approximately$15 million generated from the PIPE financing closed inJanuary 2024 .PolyPid expects that its pro forma cash balance will be sufficient to fund operations into late third quarter 2024.
Conference Call Dial-In & Webcast Information:
| Date: | |
| Time: | |
| Q&A Participants: | https://register.vevent.com/register/BI8900a42f492b4240a3bba8285558d15f |
| Webcast: | https://edge.media-server.com/mmc/p/7iigty2s |
About
For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected timing for top-line results from the SHIELD II trial and of the unblinded interim analysis, the planned NDA submission for D-PLEX100, the potential impacts and uses for OncoPLEX and the PLEX platform, the Company’s expected cash runway, and the potential to receive additional funds if warrants are exercised. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the SEC, including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed on March 31, 2023. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.
References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.
Contacts:
PolyPid Ltd.
COO – US
908-858-5995
IR@Polypid.com
Investors:
212-915-2578
britchie@lifesciadvisors.com
| CONSOLIDATED BALANCE SHEETS | ||||||||
| U.S. dollars in thousands | ||||||||
| 2023 | 2022 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | 5,309 | $ | 8,552 | ||||
| Restricted deposits | 300 | 511 | ||||||
| Short-term deposits | - | 4,042 | ||||||
| Prepaid expenses and other current assets | 458 | 1,089 | ||||||
| Total current assets | 6,067 | 14,194 | ||||||
| LONG-TERM ASSETS: | ||||||||
| Property and equipment, net | 7,621 | 9,247 | ||||||
| Operating lease right-of-use assets | 1,597 | 2,431 | ||||||
| Other long-term assets | 87 | 99 | ||||||
| Total long-term assets | 9,305 | 11,777 | ||||||
| Total assets | $ | 15,372 | $ | 25,971 | ||||
| CONSOLIDATED BALANCE SHEETS | ||||||||
| U.S. dollars in thousands (except share and per share data) | ||||||||
| 2023 | 2022 | |||||||
| (Unaudited) | ||||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Current maturities of long-term debt | $ | 4,003 | $ | 4,024 | ||||
| Accrued expenses and other current liabilities | 1,971 | 2,429 | ||||||
| Trade payables | 772 | 1,141 | ||||||
| Current maturities of operating lease liabilities | 540 | 959 | ||||||
| Total current liabilities | 7,286 | 8,553 | ||||||
| LONG-TERM LIABILITIES: | ||||||||
| Long-term debt | 6,379 | 7,574 | ||||||
| Deferred revenues | 2,548 | 2,548 | ||||||
| Long-term operating lease liabilities | 857 | 1,173 | ||||||
| Other liabilities | 398 | 294 | ||||||
| Total long-term liabilities | 10,182 | 11,589 | ||||||
| COMMITMENTS AND CONTINGENT LIABILITIES | ||||||||
| SHAREHOLDERS' EQUITY: | ||||||||
| Ordinary shares, no par value *)- | - | - | ||||||
| Authorized: 107,800,000 and 47,800,000 shares at |
||||||||
| Additional paid-in capital | 236,213 | 220,273 | ||||||
| Accumulated deficit | (238,309 | ) | (214,444 | ) | ||||
| Total shareholders' equity (deficit) | (2,096 | ) | 5,829 | |||||
| Total liabilities and shareholders' equity (deficit) | $ | 15,372 | $ | 25,971 | ||||
*) Prior period results have been retroactively adjusted to reflect the 1-for-30 reverse share split affected on
| CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||||||
| U.S. dollars in thousands (except share and per share data) |
||||||||||||
| Year Ended |
||||||||||||
| 2023 | 2022 | 2021 | ||||||||||
| (Unaudited) | ||||||||||||
| Operating expenses: | ||||||||||||
| Research and development, net | $ | 16,148 | $ | 27,990 | $ | 30,553 | ||||||
| Marketing and business development | 1,196 | 2,888 | 2,983 | |||||||||
| General and administrative | 5,523 | 8,010 | 9,609 | |||||||||
| Operating loss | 22,867 | 38,888 | 43,145 | |||||||||
| Financial (income) expense, net | 929 | 540 | (544 | ) | ||||||||
| Loss before income tax | 23,796 | 39,428 | 42,601 | |||||||||
| Income tax expense | 69 | 129 | - | |||||||||
| Net loss | $ | 23,865 | $ | 39,557 | $ | 42,601 | ||||||
| Loss per share: | ||||||||||||
| Basic | $ | 16.99 | $ | 61.09 | $ | 68.27 | ||||||
| Diluted | $ | 16.93 | $ | 61.09 | $ | 68.27 | ||||||
| Weighted-average Ordinary shares outstanding: | ||||||||||||
| Basic | 1,404,368 | 647,556 | 624,051 | |||||||||
| Diluted | 1,421,308 | 647,556 | 624,051 | |||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||
| U.S. dollars in thousands (except share and per share data) | ||||||||
| Three Months Ended |
||||||||
| 2023 | 2022 | |||||||
| (Unaudited) | (Unaudited) | |||||||
| Operating expenses: | ||||||||
| Research and development, net | $ | 4,588 | $ | 4,655 | ||||
| Marketing and business development expenses | 193 | 350 | ||||||
| General and administrative | 1,218 | 1,607 | ||||||
| Operating loss | 5,999 | 6,612 | ||||||
| Financial expense (income), net | 348 | (100 | ) | |||||
| Loss before income tax | 6,347 | 6,512 | ||||||
| Income tax expense | 9 | 55 | ||||||
| Net loss | $ | 6,356 | $ | 6,567 | ||||
| Loss per share: | ||||||||
| Basic | $ | 3.84 | $ | 9.90 | ||||
| Diluted | $ | 3.97 | $ | 9.90 | ||||
| Weighted average number of Ordinary shares used in computing basic and diluted loss per share | 1,653,559 | 663,145 | ||||||
Source: PolyPid Ltd.
